EC Number   |
Application |
Reference |
|---|
    6.3.4.5 | drug development |
high levels of AS expression, which may be required for several arginine-dependent processes in cancer, including the production of nitric oxide, proline, pyrimidines and polyamines, is regulated by TNF-alpha and may provide an important molecular pathway linking inflammation and metabolism to ovarian tumorigenesis |
674048 |
| 6.3.4.5 | medicine |
a case of late-onset CTLN1 (citrullinemia) in a patient is described by biochemical analyses and ASS gene mutation confirmation. This is the first report of a Korean patient with late-onset CTLN1 confirmed by ASS gene mutation identification |
674383 |
| 6.3.4.5 | medicine |
argininosuccinate synthase 1 is upregulated in primary human colorectal tumors and pharmacological inhibition or genetic ablation of ASS1 impairs colorectal cancer pathogenicity. ASS1 inhibition leads to reductions in the levels of oncogenic metabolite fumarate, leading to impairments in glycolytic metabolism that supports colorectal cancer cell pathogenicity |
743919 |
| 6.3.4.5 | medicine |
argininosuccinate synthase Ass contributes to ethanol plus Fas/CD95 agonistic antibody Jo2-mediated liver injury. NOS2 induction, 3-nitrotyrosine adducts formation and elevated nitrites, nitrates and S-nitrosothiols are higher in livers from wild-type mice than from Ass+/- mice |
743981 |
| 6.3.4.5 | medicine |
argininosuccinate synthase ASS1 is significantly downregulated in the urine of 30 depressed subjects while remaining unchanged in the plasma. ASS1 displays strong efficacy in distinguishing major depressive disorder subjects from healthy controls |
744740 |
| 6.3.4.5 | medicine |
argininosuccinate synthetase is inhibited by endotoxin, implying that bacterial products might potentially regulate the arginine metabolism in the host and perturb NO synthesis |
675096 |
| 6.3.4.5 | medicine |
AS and GTP cyclohydrolase I are intimately associated with inflammatory arthritis, they may be important modulators of arthritis and may represent novel targets for modulation of disease activity |
653046 |
| 6.3.4.5 | medicine |
citrulline-arginine recycling enzyme, intervention in the supply of arginine may represent a new therapeutic approach to the treatment of NO-mediated neurodegenerative damage in the brain |
653186 |
| 6.3.4.5 | medicine |
neuronal and glial ASS expression is increased in brains of patients with Alzheimer disease |
652976 |
| 6.3.4.5 | medicine |
novel target for the therapy of hypertension-related disorders |
704509 |
